IDH2 and cancer: At this point, the inhibition of glutamate processing with GDH inhibitor epigallocatechin-3-gallate (EGCG) would decrease the synthesis of NAD(P)H and α-KG in IDH-mutated cancers, resulting in increased oxidative stress and metabolic stress, and subsequently improved sensitivity to radiotherapy [71].